UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 79.598
NA - Nord America 3.247
AS - Asia 1.467
SA - Sud America 169
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 84.519
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 78.757
US - Stati Uniti d'America 3.213
SG - Singapore 577
CN - Cina 541
UA - Ucraina 256
SE - Svezia 193
BR - Brasile 132
VN - Vietnam 132
FI - Finlandia 93
DE - Germania 86
GB - Regno Unito 74
FR - Francia 62
HK - Hong Kong 53
IN - India 41
KR - Corea 32
CA - Canada 19
BD - Bangladesh 18
RU - Federazione Russa 18
IQ - Iraq 11
NL - Olanda 11
PL - Polonia 11
ZA - Sudafrica 11
AR - Argentina 10
BE - Belgio 9
JP - Giappone 9
MX - Messico 8
TR - Turchia 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
CO - Colombia 6
EU - Europa 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
CL - Cile 4
ID - Indonesia 4
IE - Irlanda 4
KE - Kenya 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
SV - El Salvador 2
VE - Venezuela 2
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ES - Italia 1
ET - Etiopia 1
GA - Gabon 1
HR - Croazia 1
KW - Kuwait 1
LU - Lussemburgo 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 84.519
Salva come PNG Salva come JPEG
Città #
Cagliari 77.529
Uta 1.071
Singapore 315
Ashburn 297
Woodbridge 294
Fairfield 287
Chandler 264
Ann Arbor 143
San Jose 143
Jacksonville 138
Nyköping 136
Houston 131
Seattle 124
Boardman 117
Wilmington 117
Dallas 102
Dearborn 101
Cambridge 97
Beijing 95
New York 74
Los Angeles 72
Helsinki 54
Santa Clara 50
Hong Kong 41
Nanjing 40
Shanghai 37
Ho Chi Minh City 35
Lauterbourg 35
Hefei 32
Boston 31
Seoul 29
Guangzhou 26
Hanoi 25
Milan 23
Council Bluffs 22
Buffalo 21
Shenyang 20
The Dalles 20
Redwood City 19
San Diego 18
Dong Ket 16
Jinan 15
Hebei 13
Orem 13
Norwalk 12
Changsha 11
Jiaxing 11
Mountain View 10
Munich 10
Toronto 10
Brussels 9
Frankfurt am Main 9
Nanchang 9
Redondo Beach 9
Hangzhou 8
London 8
Orange 8
Phoenix 8
Brooklyn 7
Chicago 7
Dhaka 7
Düsseldorf 7
São Paulo 7
Tianjin 7
Verona 7
Haiphong 6
Ningbo 6
Oristano 6
Padova 6
Tashkent 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Amsterdam 5
Atlanta 5
Belo Horizonte 5
Modrice 5
Montreal 5
Pune 5
Rio de Janeiro 5
Rome 5
Tokyo 5
Baghdad 4
Campinas 4
Chengdu 4
Chennai 4
Da Nang 4
Gurgaon 4
Indore 4
Kathmandu 4
Kunming 4
La Paz 4
Manchester 4
Mexico City 4
Nuremberg 4
Paris 4
Portsmouth 4
Sassari 4
Stockholm 4
Thái Nguyên 4
Totale 82.628
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.476
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.249
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.161
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.118
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 3.010
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.937
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.849
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.762
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.720
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.699
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.685
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.662
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.627
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.538
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.487
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.419
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.232
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.203
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.166
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.118
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.095
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.090
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.966
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.944
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.883
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.866
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.750
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.702
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.648
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.635
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.414
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.284
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.282
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.167
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.097
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 1.003
null 981
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 945
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 556
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 329
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 269
Totale 84.675
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.045
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.045
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.022 0 0 0 0 0 0 0 0 0 692 741 589
2021/20223.751 333 284 320 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20256.979 1.324 1.426 1.166 910 527 563 607 71 116 77 102 90
2025/20262.613 219 117 258 173 251 225 764 144 171 291 0 0
Totale 84.675